Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Price Crosses Above 50-Day Moving Average – Time to Sell?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)’s share price crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $66.96 and traded as high as $68.71. Global X Genomics & Biotechnology ETF shares last traded at $67.90, with a volume of 30,031 shares.

Global X Genomics & Biotechnology ETF Stock Performance

The stock’s fifty day moving average is $66.96 and its two-hundred day moving average is $53.96. The firm has a market cap of $107.28 million, a price-to-earnings ratio of -29.02 and a beta of 1.17.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its holdings in shares of Global X Genomics & Biotechnology ETF by 67.8% during the first quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock valued at $5,240,000 after purchasing an additional 48,394 shares during the period. Polaris Financial Partners bought a new stake in shares of Global X Genomics & Biotechnology ETF during the third quarter valued at about $1,067,000. Wealth Management Partners LLC raised its stake in shares of Global X Genomics & Biotechnology ETF by 143.3% during the third quarter. Wealth Management Partners LLC now owns 24,677 shares of the company’s stock valued at $1,739,000 after purchasing an additional 14,533 shares in the last quarter. Farther Finance Advisors LLC bought a new stake in shares of Global X Genomics & Biotechnology ETF during the third quarter valued at about $257,000. Finally, Commonwealth Equity Services LLC acquired a new stake in Global X Genomics & Biotechnology ETF in the third quarter worth about $220,000. 56.95% of the stock is owned by institutional investors.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.